Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Dissociative or Tryptamine or targets protofibrils

Use the filters below to narrow your results.

generic:
None (2)
brand:
None (43) · DXM (1) · DXO (1) · Leqembi (1) · Spravato (1)
classes: (Click arrow to add another value)
mechanism:
None (2) · 5-HT2A agonist (15) · 5-HT2A agonist; 5-HT3 antagonist (1) · 5-HT2A agonist; minor psilocybin mushroom alkaloid (1) · 5-HT2A agonist; primarily auditory effects (1) · 5-HT2A agonist; sigma-1 agonist (1) · Active metabolite of DXM; NMDA antagonist (1) · Contains salvinorin A (1) · Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) · Kappa-opioid receptor agonist (1) · Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) · NMDA antagonist (3) · NMDA antagonist; endogenous opioid releaser (1) · NMDA antagonist; fluorinated ketamine analogue (1) · NMDA antagonist; kappa-opioid agonist (1) · NMDA antagonist; ketamine analogue (1) · NMDA antagonist; more stimulating than PCP (1) · NMDA antagonist; opioid agonist (1) · NMDA antagonist; potent opioid agonist (1) · NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) · NMDA antagonist; sigma receptor agonist (2) · NMDA antagonist; sigma receptor agonist; dopaminergic (1) · NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) · Potent 5-HT2A agonist; sigma-1 agonist (1) · Prodrug of 4-HO-DET; 5-HT2A agonist (1) · Prodrug of 4-HO-DiPT; 5-HT2A agonist (1) · Prodrug of 4-HO-MET; 5-HT2A agonist (1) · Prodrug of 4-HO-MiPT; 5-HT2A agonist (1) · Prodrug of psilocin; 5-HT2A agonist (1)
uses:
None (45) · Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023 (1) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)
starting dose:
None (45) · 10 mg/kg IV every 2 weeks (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
preparations:
None (45) · 200 mg/2 mL, 500 mg/5 mL vials for IV infusion (1) · 28 mg/device (each dose uses 2 devices) (1)
fda max:
None (45) · 10 mg/kg q2w (1) · 84 mg per session (1)
routes:
None (45) · Intranasal (under direct medical supervision) (1) · IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting (1)
onset:
None (45) · Slowing of cognitive decline over 18 months (modest effect, ~27% relative slowing) (1) · Within hours of first administration (1)
duration:
None (45) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1) · Ongoing dosing (1)
halflife:
None (45) · ~5-7 days (1) · ~7-12 hours (1)
bioavailability:
None (45) · 100% (IV) (1) · ~48% intranasal (1)
pregnancy:
None (45) · Avoid; may cause fetal harm (1) · Limited data (1)
legal:
None (45) · Rx, Schedule III (US). REMS program required. (1) · Rx; REMS-like program for ARIA monitoring (1)

Showing below up to 47 results in range #1 to #47.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"